Barclays
ARRY

Barclays’s Array Biopharma Inc ARRY Stock Holding History

Barclays’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10,000
Closed -$463K – 7461
2019
Q2 		$463K Buy
10,000
+7,700
+335% +$216K ﹤0.01% 4381
2019
Q1 		$56K Buy
2,300
+1,600
+229% +$33.3K ﹤0.01% 5797
2018
Q4 		$10K Hold
700
– – ﹤0.01% 6193
2018
Q3 		$11K Sell
700
-55,800
-99% -$855K ﹤0.01% 6643
2018
Q2 		$948K Buy
56,500
+54,200
+2,357% +$862K ﹤0.01% 3347
2018
Q1 		$38K Sell
2,300
-4,000
-63% -$64.1K ﹤0.01% 6105
2017
Q4 		$81K Hold
6,300
– – ﹤0.01% 5410
2017
Q3 		$77K Sell
6,300
-75,900
-92% -$705K ﹤0.01% 5108
2017
Q2 		$688K Buy
82,200
+81,800
+20,450% +$669K ﹤0.01% 3214
2017
Q1 		$4K Buy
+400
New +$4.26K ﹤0.01% 6360

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Barclays's ARRY Position: Q3 2019 in Review

Barclays sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 586,743 shares — an estimated $27.2M sold.

Barclays first reported a position in ARRY in Q2 2013 and held it in 24 quarters. The position peaked at $27.2M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Barclays reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Barclays sold 586,743 Array Biopharma Inc shares in Q3 2019, an estimated $27.2M.
  • Barclays first reported a position in Array Biopharma Inc in Q2 2013 and held it in 24 quarters.
  • Barclays's Array Biopharma Inc position peaked at $27.2M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Barclays's 13F filing for Q3 2019, filed 14 Nov 2019.